Table 4. Univariate and multivariate ORs for severity of LV remodeling.
| Characteristics | Outcome |
Univariate |
Multivariate |
|||
|---|---|---|---|---|---|---|
| Not wourse | Worse | OR (95% CI) | P value | OR (95% CI) | P value | |
| Age (year) per 1 year | 0.998 (0.963–1.035) | 0.928 | 1.007 (0.957–1.058) | 0.796 | ||
| Sex | ||||||
| Male | 15 | 44 | 1 | 1 | ||
| Female | 5 | 8 | 0.545 (0.154–1.926) | 0.346 | 0.647 (0.118–3.540) | 0.615 |
| β-blocker usage | ||||||
| No | 19 | 48 | 1 | 1 | ||
| Yes | 1 | 4 | 1.583 (0.166–15.094) | 0.690 | 0.697 (0.026–18.520) | 0.829 |
| Diabetes mellitus | ||||||
| No | 15 | 41 | 1 | 1 | ||
| Yes | 5 | 11 | 0.805 (0.240–2.703) | 0.725 | 0.262 (0.033–2.094) | 0.206 |
| Hypertension | ||||||
| No | 8 | 18 | 1 | 1 | ||
| Yes | 12 | 34 | 1.259 (0.436–3.640) | 0.670 | 1.162 (0.175–7.694) | 0.876 |
| Combined | ||||||
| 0 | 15 | 12 | 1 | 1 | ||
| 1 | 3 | 15 | 6.250 (1.461–26.739) | 0.013 | 9.973 (1.371–72.559) | 0.023 |
| 2 | 2 | 25 | 15.625 (3.067–79.594) | 0.001 | 24.645 (2.869–211.698) | 0.003 |
| Hs-CRP per 1 | 0.994 (0.973–1.015) | 0.570 | 0.998 (0.969–1.028) | 0.898 | ||
| Creatinine per 1 | 0.976 (0.945–1.008) | 0.137 | 0.990 (0.949–1.033) | 0.643 | ||
| LVEDD per 1 | 0.998 (0.898–1.108) | 0.963 | 0.925 (0.784–1.091) | 0.354 | ||
| EF per 1 | 0.948 (0.898–1.002) | 0.059 | 0.908 (0.828–0.996) | 0.041 | ||
Combined 1: (Catestatin>28.71 ng/ml & NT-proBNP<472 pg/ml or Catestatin<28.71 ng/ml & NT-proBNP>472 pg/ml) vs. (Catestatin<28.71 ng/ml & NT-proBNP<472 pg/ml); Combined 2: (Catestatin>28.71 ng/ml & NT-proBNP>472 pg/ml) vs. (Catestatin<28.71 ng/ml & NT-proBNP<472 pg/ml). Hs-CRP, high-sensitivity C-reactive protein; LVEDD, left ventricular end-diastolic dimension; EF; ejection fraction.